Head and Neck Cancer Stem Cell-Enriched Spheroid Model for Anticancer Compound Screening.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
16 07 2020
Historique:
received: 17 06 2020
revised: 10 07 2020
accepted: 14 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 6 3 2021
Statut: epublish

Résumé

Cancer stem cells (CSCs), a rare cell population in tumors, are resistant to conventional chemotherapy and thus responsible for tumor recurrence. To screen for active compounds targeting CSCs, a good CSC-enriched model compatible with high-throughput screening (HTS) is needed. Here, we describe a new head and neck cancer stem cell-enriched spheroid model (SCESM) suitable for HTS analyses of anti-CSC compounds. We used FaDu cells, round-bottom ultra-low adherent (ULA) microplates, and stem medium. The formed spheroids displayed increased expression of all stem markers tested (qRT-PCR and protein analysis) in comparison to the FaDu cells grown in a standard adherent culture or in a well-known HTS-compatible multi-cellular tumor spheroid model (MCTS). Consistent with increased stemness of the cells in the spheroid, confocal microscopy detected fast proliferating cells only at the outer rim of the SCESM spheroids, with poorly/non-proliferating cells deeper in. To confirm the sensitivity of our model, we used ATRA treatment, which strongly reduced the expression of selected stem markers. Altogether, we developed a CSC-enriched spheroid model with a simple protocol, a microplate format compatible with multimodal detection systems, and a high detection signal, making it suitable for anti-CSC compounds' HTS.

Identifiants

pubmed: 32708734
pii: cells9071707
doi: 10.3390/cells9071707
pmc: PMC7408407
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Tretinoin 5688UTC01R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Cancer Treat Rev. 2016 Sep;49:25-36
pubmed: 27434881
Oncotarget. 2016 Jan 12;7(2):1215-26
pubmed: 26527320
Trends Pharmacol Sci. 2019 Mar;40(3):161-171
pubmed: 30709543
J Vis Exp. 2018 Jan 10;(131):
pubmed: 29364250
Expert Opin Drug Discov. 2012 Sep;7(9):819-30
pubmed: 22788761
Mol Cancer. 2020 Jan 11;19(1):7
pubmed: 31926547
Stem Cell Res Ther. 2018 Sep 26;9(1):243
pubmed: 30257704
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
Head Neck. 2013 Mar;35(3):413-9
pubmed: 22422628
Clin Cancer Res. 2008 Jul 1;14(13):4085-95
pubmed: 18593985
J Cancer. 2016 Apr 02;7(6):736-45
pubmed: 27076856
J Oral Pathol Med. 2007 Nov;36(10):594-603
pubmed: 17944752
Br J Cancer. 2014 Jul 29;111(3):506-14
pubmed: 24874475
Methods Mol Biol. 2018;1683:355-369
pubmed: 29082502
Methods Mol Biol. 2016;1439:1-32
pubmed: 27316985
BMC Cancer. 2016 Sep 30;16(Suppl 2):738
pubmed: 27766946
J R Soc Interface. 2014 Jan 15;11(92):20131124
pubmed: 24430128
J Exp Clin Cancer Res. 2017 Aug 3;36(1):102
pubmed: 28774341
SLAS Discov. 2017 Jun;22(5):456-472
pubmed: 28520521
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Cell. 2009 Aug 21;138(4):645-659
pubmed: 19682730
Bioessays. 2016 Jul;38 Suppl 1:S65-74
pubmed: 27417124
Cell Tissue Res. 2019 Feb;375(2):397-408
pubmed: 30244317
Exp Cell Res. 2016 Oct 15;348(1):75-86
pubmed: 27619333
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
J Clin Pathol. 2018 Jan;71(1):88-91
pubmed: 29180509
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6
pubmed: 15142631
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Lancet Oncol. 2012 Feb;13(2):e83-9
pubmed: 22300863
Stem Cell Investig. 2019 Aug 05;6:21
pubmed: 31559308
Cell Death Discov. 2017 Jan 23;3:16105
pubmed: 28179999
Can J Physiol Pharmacol. 2017 Jan;95(1):1-15
pubmed: 27925473
J Cell Physiol. 2020 Jan;235(1):65-73
pubmed: 31206697
Stem Cells Int. 2011;2011:504723
pubmed: 21603148
PLoS One. 2010 Jul 06;5(7):e11456
pubmed: 20625515
Mol Nutr Food Res. 2012 Aug;56(8):1247-58
pubmed: 22692956
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Assay Drug Dev Technol. 2016 Jan-Feb;14(1):19-28
pubmed: 26866750
J Clin Pathol. 2013 Nov;66(11):928-32
pubmed: 23940132
SLAS Discov. 2020 Apr;25(4):329-349
pubmed: 31983262
Biomed Pharmacother. 2019 Sep;117:108998
pubmed: 31207579
BMC Cancer. 2017 May 18;17(1):338
pubmed: 28521819
Leukemia. 2018 Jan;32(1):159-167
pubmed: 28626219
Exp Biol Med (Maywood). 2016 May;241(9):939-54
pubmed: 27072562
Drug Discov Today Technol. 2017 Mar;23:27-36
pubmed: 28647083
J Oral Pathol Med. 2018 May;47(5):492-501
pubmed: 29575240
Assay Drug Dev Technol. 2019 Jan;17(1):17-36
pubmed: 30592624
ScientificWorldJournal. 2014 Jan 21;2014:842491
pubmed: 24574924
Immunopharmacol Immunotoxicol. 2011 Jun;33(2):241-9
pubmed: 20929432
Mol Cancer Ther. 2015 Jun;14(6):1504-16
pubmed: 25911689
Mol Med Rep. 2012 Sep;6(3):519-24
pubmed: 22684859
Cancers (Basel). 2019 May 02;11(5):
pubmed: 31052565
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Cancer Lett. 2010 Mar 28;289(2):151-60
pubmed: 19748175
PLoS One. 2011;6(12):e28856
pubmed: 22174914
Assay Drug Dev Technol. 2018 Jan;16(1):27-50
pubmed: 29215913
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2017 Aug 3;9(1):1326-1345
pubmed: 29416698
J Natl Cancer Inst. 2006 Apr 5;98(7):441-50
pubmed: 16595780
Biol Rev Camb Philos Soc. 2017 Aug;92(3):1505-1520
pubmed: 27545872
Folia Biol (Praha). 2014;60(5):205-12
pubmed: 25863037

Auteurs

Larisa Goričan (L)

Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, SI-2000 Maribor, Slovenia.

Boris Gole (B)

Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, SI-2000 Maribor, Slovenia.

Uroš Potočnik (U)

Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, SI-2000 Maribor, Slovenia.
Laboratory for Biochemistry, Molecular biology and Genomics, Faculty of Chemistry and Chemical Engineering, University of Maribor, SI-2000 Maribor, Slovenia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH